2012 TADO – A phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients with Sickle Cell Disease Case StudiesClosed out 2012 TADO – A phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients with Sickle Cell Disease
2015/2016 HESTIA 1 – Multicenter, Open-label, Randomized, Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging, Phase 2 Study of Ticagrelor followed by a Double-blind, randomized, Parallel group, Placebo-controlled 4 weeks extension Phase in Pediatric Patients with Sickle Cell Disease Case StudiesClosed out 2015/2016 HESTIA 1 – Multicenter, Open-label, Randomized, Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging, Phase 2 Study of Ticagrelor followed by a Double-blind, randomized, Parallel group, Placebo-controlled 4 weeks extension Phase in Pediatric Patients with Sickle Cell Disease
2018 HESTIA 4 – A Multi-centre, Phase 1, Open-label, Single-Dose Study to Investigate Pharmacokinetics (PK) of Ticagrelor in Infants and Toddlers, Aged 0 to less than 24 months, with Sickle Cell Disease Case StudiesClosed out 2018 HESTIA 4 – A Multi-centre, Phase 1, Open-label, Single-Dose Study to Investigate Pharmacokinetics (PK) of Ticagrelor in Infants and Toddlers, Aged 0 to less than 24 months, with Sickle Cell Disease
2019 HESTIA 3 – A Randomised, Double-Blind, Parallel-Group, Multi-centre, Phase 3 Study to Evaluate the Effect of Ticagrelor vs Placebo in Reducing the Rate of Vaso-Occlusive Crises in Pediatric Patients with Sickle Cell Disease Case StudiesClosed out 2019 HESTIA 3 – A Randomised, Double-Blind, Parallel-Group, Multi-centre, Phase 3 Study to Evaluate the Effect of Ticagrelor vs Placebo in Reducing the Rate of Vaso-Occlusive Crises in Pediatric Patients with Sickle Cell Disease
2017 GBT 031 – A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multi-Centre Study of GBT 440 Administered Orally to Patients with Sickle Cell Disease Case StudiesClosed out 2017 GBT 031 – A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multi-Centre Study of GBT 440 Administered Orally to Patients with Sickle Cell Disease
2020 IMR-SCD-301 ‘IMARA’ – A Phase 2b Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with Sickle Cell Disease Case StudiesClosed out 2020 IMR-SCD-301 ‘IMARA’ – A Phase 2b Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with Sickle Cell Disease
